Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has granted equity inducement awards to 11 new non-executive employees.
Under the company's 2025 Inducement Plan, the employees received a total of 6,940 time-based restricted stock units. These units will vest in four equal annual installments, subject to continued employment. The awards were approved by Madrigal's independent Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4).
Madrigal Pharmaceuticals (NASDAQ:MDGL), azienda biofarmaceutica focalizzata su terapie per la steatoepatite associata a disfunzione metabolica (MASH), ha assegnato premi azionari incentivanti a 11 nuovi dipendenti non dirigenti.
Ai sensi del Piano di Induzione 2025 della società, i dipendenti hanno ricevuto complessivamente 6.940 unità di stock restricted time-based. Tali unità matureranno in quattro rate annuali uguali, subordinate alla permanenza in servizio. Gli incentivi sono stati approvati dal Comitato Indipendente per la Retribuzione di Madrigal, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Madrigal Pharmaceuticals (NASDAQ:MDGL), una compañía biofarmacéutica especializada en terapias para la esteatohepatitis asociada a disfunción metabólica (MASH), ha otorgado incentivos accionarios a 11 nuevos empleados no ejecutivos.
En virtud del Plan de Inducción 2025 de la empresa, los empleados recibieron un total de 6.940 unidades restringidas de acciones basadas en el tiempo. Estas unidades se consolidarán en cuatro pagos anuales iguales, condicionados a la continuidad laboral. Los premios fueron aprobados por el Comité de Compensación independiente de Madrigal, conforme a la Norma de Cotización de Nasdaq 5635(c)(4).
Madrigal Pharmaceuticals (NASDAQ:MDGL)는 대사 이상 관련 지방간염(MASH) 치료제를 개발하는 바이오 제약사로서 11명의 신규 비임원 직원에게 주식 인센티브를 부여했습니다.
회사의 2025 인덕션 플랜에 따라 해당 직원들은 총 6,940개의 시간 기반 제한부 주식단위(RSU)를 받았습니다. 이 단위들은 근속을 조건으로 4년에 걸쳐 매년 동일한 비율로 베스팅됩니다. 이 상여는 나스닥 상장 규칙 5635(c)(4)에 따라 Madrigal의 독립 보상위원회의 승인을 받았습니다.
Madrigal Pharmaceuticals (NASDAQ:MDGL), une société biopharmaceutique spécialisée dans les traitements de la stéatohépatite associée à un dysfonctionnement métabolique (MASH), a accordé des attributions de titres à 11 nouveaux employés non cadres.
Dans le cadre du Plan d'Inducement 2025 de la société, les employés ont reçu au total 6 940 unités d'actions restreintes liées au temps. Ces unités se révèleront en quatre versements annuels égaux, sous réserve de la poursuite de l'emploi. Les attributions ont été approuvées par le comité indépendant de rémunération de Madrigal, conformément à la règle de cotation Nasdaq 5635(c)(4).
Madrigal Pharmaceuticals (NASDAQ:MDGL), ein biopharmazeutisches Unternehmen mit Schwerpunkt auf Therapien gegen metabolisch bedingte Steatohepatitis (MASH), hat 11 neuen nicht-exekutiven Mitarbeitern Aktieneinführungsprämien gewährt.
Im Rahmen des 2025 Inducement Plans des Unternehmens erhielten die Mitarbeiter insgesamt 6.940 zeitgebundene Restricted Stock Units. Diese Einheiten lösen sich in vier gleichen jährlichen Tranchen frei, vorbehaltlich der fortgesetzten Beschäftigung. Die Zuteilungen wurden vom unabhängigen Vergütungsausschuss von Madrigal gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- None.
- None.
CONSHOHOCKEN, Pa., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2025 to 11 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 6,940 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
What equity awards did Madrigal Pharmaceuticals (MDGL) grant to new employees in August 2025?
How will the restricted stock units vest for Madrigal Pharmaceuticals' new employees?
When did Madrigal Pharmaceuticals (MDGL) grant these inducement awards?
What is the purpose of Madrigal Pharmaceuticals' inducement awards?
